SBCWW · SBC Medical Group Holdings Inc
Price & Indicators
The closing range uses available history since Jul 24, 2026; less than a full year is stored.
Up next
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $38M | 1H 2026 | — |
| Adjusted EBITDA margin non-GAAP | 42% | Six Months Ended June 30, 2026 | — |
| Average spend per visit | $287 | Q2 2026 | — |
| last-twelve-month number of visits | 6.9M | LTM ended June 30, 2026 | — |
| number of locations | 287 | As of the end of June 2026 | — |
| ROE (Annualized) | 16% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Consulting Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SBCWW
this stock
SBC Medical Group Holdings Inc
|
$573.89M | — | -15.5% | — | — |
|
VRSK
Verisk Analytics, Inc.
|
$24.81B | -14.7% | +6.6% | 29.1 | 3.4% |
|
EFX
Equifax Inc
|
$20.99B | -17.3% | +6.9% | 29.0 | 4.8% |
|
BAH
Booz Allen Hamilton Holding Corp
|
$9.99B | -0.2% | -6.4% | 13.1 | 5.6% |
|
FCN
Fti Consulting, Inc
|
$4.94B | +6.1% | +2.4% | 22.6 | 11.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SBCWW | +12.7% | +35.3% | — | +35.3% | — |
| SPY | +0.7% | +0.7% | +4.3% | +0.9% | +12.8% |
| vs SPY | +12.0% | +34.6% | — | +34.4% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.